La chirurgie des masses résiduelles

  • N. Mottet
Part of the Monographies en urologie book series (MONOGRAPHIES)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones WG, Stenning SP, Read G et al. (1998) Long term follow-up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC study TE16): a preliminary report. In Jones WG, Appleyard I, Harnder P, Joffe JK (eds). Germ cell tumours IV. John Libbey London. pp 260Google Scholar
  2. 2.
    Steyerberg EW, Keizer HJ, Stoter G et al. (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30A(9): 1231–9PubMedGoogle Scholar
  3. 3.
    Janet E S Husband, DM Koh, GJR Cook (2003) Radiologic investigation. In D. Raghavan (eds): Germ Cell Tumors. BC Decker Inc Hamilton p 58–73Google Scholar
  4. 4.
    Tavernier E, Fléchon A, Méeus P et al. (2004) Indication of post-chemotherapy retroperitoneal lymph node dissection (RPLND) in the treatment of non seminomatous germ cell tumors of the testis (NSGCTT): the case of minimal initial and residual disease. J Clin Oncol 23: 405 #4599Google Scholar
  5. 5.
    Fléchon A, Bompas E, Biron P et al. (2002) Management of post-chemotherapy residual masses in advanced seminoma. J Urol 168: 1975–9PubMedGoogle Scholar
  6. 6.
    Friedman EL, Garnick MB, Stomper PC et al. (1985) Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 3: 1325–32PubMedGoogle Scholar
  7. 7.
    Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128: 315–20PubMedGoogle Scholar
  8. 8.
    Donohue JP, Roth LM, Zachary JM et al. (1982) Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol 127: 1111–4PubMedGoogle Scholar
  9. 9.
    Michel F, Petit M, Kouri G et al. (2003) Les complications et séquelles des curages lymphonodaux rétropéritonéaux. Progrès en Urologie 13: 155–8Google Scholar
  10. 10.
    Donohue JP, Rowland RG (1981) Complications of retroperitoneal lymph node dissection J Urol 125: 338–40PubMedGoogle Scholar
  11. 11.
    Skinner DG, Melamud A, Lieskovsky G (1982) Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol 127: 1107–110PubMedGoogle Scholar
  12. 12.
    Mosharafa AA, Foster RS, Koch MO et al. (2004) Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171: 1839–41PubMedGoogle Scholar
  13. 13.
    Pizzocaro G (2003) Surgery of metastatic disease after chemotherapy. In D. Raghavan (eds) Germ Cell Tumors. BC Decker Inc Hamilton. p 109Google Scholar
  14. 14.
    Logothetis CJ, Samuels ML, Trindate A (1982) The growing teratoma syndrome. Cancer: 50: 1629–35PubMedGoogle Scholar
  15. 15.
    Sonneveld DJ, Sleijfer DT, Koops HS et al. (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 82: 1343–51PubMedCrossRefGoogle Scholar
  16. 16.
    Andre F, Fizazi K, Culine S et al. (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 36: 1389–94PubMedGoogle Scholar
  17. 17.
    Spermon JR, De Geus-Oei LF, Kiemeney LA et al. (2002) The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89: 549–56PubMedGoogle Scholar
  18. 18.
    Horwich A (2003) Chemotherapy for metastatic seminoma. In D. Raghavan (eds). Germ Cell Tumors. BC Decker Inc Hamilton. p 236Google Scholar
  19. 19.
    Herr HW, Sheinfeld J, Puc HS et al. (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157: 860–2PubMedGoogle Scholar
  20. 20.
    De Santis M, Becherer A, Bokemeyer C (2003) FDG-PET as prognostic indicator for seminoma residuals: an update from the multicenter SEMPET study. J Clin Oncol 22: 382. #1535Google Scholar
  21. 21.
    Oldenburg J, Alfsen GC, Lien HH et al. (2003) Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21: 3310–17PubMedCrossRefGoogle Scholar
  22. 22.
    Karapetis CS, Strickland AH, Yip D et al. (2003) Use of fluorodeoxyglucose positron emission tomography scan in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long term follow up. Intern med J 33: 427–35PubMedCrossRefGoogle Scholar
  23. 23.
    Sheinfeld J, Motzer R (2004) Editorial: Predicting necrosis after chemotherapy for advanced non seminomatous germ cell tumor — surcroît end points, decrescendo morbidity and patient outcome. J Urol 171: 1842–3PubMedGoogle Scholar
  24. 24.
    Vergouwe Y, Steyerberg EW, Foster RS et al. (2001) Validation of a prediction model and its representators for the histology of residual masses in non seminomatous testicular cancer. J Urol 165: 84–8PubMedCrossRefGoogle Scholar
  25. 25.
    Donohue JP, Rowland RG, Kopecky K et al. (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137: 1176–9PubMedGoogle Scholar
  26. 26.
    Steyerberg EW, Ger A, Fossa SD (1988) Valididy of predictions of residual retroperitoneal mass histology in non-seminomatous testicular cancer. J Clin Oncol 16: 269–74Google Scholar
  27. 27.
    Albers P, Weissbach L, Krege S et al. (2004) Prediction of necrosis after chemotherapy of avanced germ cell tumors: results of a prospective multicenter trial of the german testicular cancer study group. J Urol 171: 1835–8PubMedGoogle Scholar
  28. 28.
    Puc HS, Heelan R, Mazumdar M et al. (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14(2): 454–60PubMedGoogle Scholar
  29. 29.
    Ravi R, Ong J, Oliver RT et al. (1999) The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 83: 649–53PubMedGoogle Scholar
  30. 30.
    Horwich A, Paluchowska B, Norman A et al. (1997) Residual mass following chemotherapy of seminoma. Ann Oncol (1): 37–40Google Scholar
  31. 31.
    Hartmann JT, Candelaria M, Kuczyk MA et al. (1997). Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–7PubMedGoogle Scholar
  32. 32.
    Steyerberg EW, Donohue JP, Gerl A et al. (1997) Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 158: 474–8PubMedGoogle Scholar
  33. 33.
    Houlgatte A et le sous-comité Organes génitaux externes du Comité de cancérologie de l’Association française d’Urologie (2003) Prise en charge des métastases lymphonodales rétropéritonéales des tumeurs germinales du testicule. Progrès en Urologie 13: 147–59PubMedGoogle Scholar
  34. 34.
    Steiner H, Peschel R, Janetschek G et al. (2004) Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 63: 550–5PubMedCrossRefGoogle Scholar
  35. 35.
    Janetschek G, Hobisch A, Peschel R et al. (2000) Laparoscopic retroperitoneal lymph node dissection. Urology 55: 136–40PubMedCrossRefGoogle Scholar
  36. 36.
    Peschel R, Gettman MT, Neururer R et al. (2002) Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique. Urology 60: 339–43PubMedCrossRefGoogle Scholar
  37. 37.
    Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60: 130–4PubMedCrossRefGoogle Scholar
  38. 38.
    Donohue JP (1997) Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprahilar dissection. Urol Clin North Amer 4: 509Google Scholar
  39. 39.
    Skinner DG (1977) Consideration for management of large retroperitoneal tumors: use of the modified thoraco-abdominal approach. J Urol 117: 605–9PubMedGoogle Scholar
  40. 40.
    Waters WB, Manecke R (2000) Resection of metastatic disease. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Genito-urinary Oncology. Lippincott Philadelphia. p 961Google Scholar
  41. 41.
    Mosharafa AA, Foster RS, Koch MO et al. (2004) Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171: 1839–41PubMedGoogle Scholar
  42. 42.
    Donat SM, Levy DA. (1998) Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary ? J Urol 160(4): 1347–1352PubMedGoogle Scholar
  43. 43.
    Dahl AA, Fossa SD (2004) Sexual functioning in long term survivors of testicular cancer. J Clin Oncol 23: 387 #4526Google Scholar
  44. 44.
    Donohue JP, Foster RS, Rowland RG et al. (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144: 287–91PubMedGoogle Scholar
  45. 45.
    Wood DP Jr, Herr HW, Heller G et al. (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148: 1812–5PubMedGoogle Scholar
  46. 46.
    Herr HW (1997) Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer ? Br J Urol 80: 653–7PubMedGoogle Scholar
  47. 47.
    Ozen H, Ekici S, Sozen S et al. (2001) Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. Urology 57: 323–7PubMedGoogle Scholar
  48. 48.
    Flechon A, Tavernier E, Méeus P et al. (2004) Study of the conformity of post-chemotherapy retroperitoneal lymph node dissection to standard recommendations in patients with testicular and primary retroperitoneal non seminomatous germ cell tumor: impact on outcome. J Clin Oncol 23: 401 # 4584Google Scholar
  49. 49.
    Beck SDW, Patel MI, Sheinfeld J (2004) Tumor marker levels in post-chemotherapy in post chmeotherapy cyctis masses: clinical implications for patients with germ cell tumors. J Urol 171: 168–71PubMedCrossRefGoogle Scholar
  50. 50.
    Albers P, Ganz A, Hannig E et al. (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164: 381–4PubMedCrossRefGoogle Scholar
  51. 51.
    Quinn DI, Hamid O, Streeter OE et al. (2003) Central nervous system metastases. In D. Raghavan (eds) Germ Cell Tumors. BC Decker Inc Hamilton. p 199Google Scholar
  52. 52.
    Fizazi K, Tjulandin S, Salvioni R et al. (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy — results from an international study group. J Clin Oncol 19: 2647–57PubMedGoogle Scholar
  53. 53.
    International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: A prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603Google Scholar

Copyright information

© Springer-Verlag France, Paris 2006

Authors and Affiliations

  • N. Mottet
    • 1
  1. 1.Clinique MutualisteSaint-Étienne Cedex 2

Personalised recommendations